Search research articles
Contact Us
Filters
Showing results (41-50 of 49) with videos related to
Page
of 5
Sort By:
You have reached the last page of results.
This site can display upto 49 results.
Urologia Internationalis
|
February 4, 2024
Sunitinib for Metastatic Renal Cell Carcinoma: Real-World Data from the STAR-TOR Registry and Detailed Literature Review
Annemarie Uhlig, Lothar Bergmann, Martin Bögemann, et al.
BMC Cancer
|
May 1, 2015
Everolimus in metastatic renal cell carcinoma after failure of initial anti-VEGF therapy: final results of a noninterventional study
Lothar Bergmann, Ulrich Kube, Christian Doehn, et al.
Future Oncology (London, England)
|
September 23, 2020
Consensus paper: current state of first- and second-line therapy in advanced clear-cell renal cell carcinoma
Peter J Goebell, Philipp Ivanyi, Jens Bedke, et al.
Onkologie
|
March 15, 2013
Everolimus in metastatic renal cell carcinoma after failure of initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy: results of an interim analysis of a non-interventional study
Lothar Bergmann, Peter J Goebell, Ulrich Kube, et al.
Oncology Research and Treatment
|
April 2, 2014
Treatment algorithm for metastatic renal cell carcinoma--recommendations based on evidence and clinical practice
Lothar Bergmann, Jochaim Beck, Kathrin Bothe, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 31, 2019
Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma
Frede Donskov, Robert J Motzer, Eric Voog, et al.
European Urology
|
September 27, 2023
Nivolumab Switch Maintenance Therapy After Tyrosine Kinase Inhibitor Induction in Metastatic Renal Cell Carcinoma: A Randomized Clinical Trial by the Interdisciplinary Working Group on Renal Tumors of the German Cancer Society (NIVOSWITCH; AIO-NZK-0116ass)
Viktor Grünwald, Philipp Ivanyi, Stefanie Zschäbitz, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 3, 2026
Papillary renal cell carcinoma - exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological review
Marit Ahrens, John Haanen, Laurence Albiges, et al.
Journal of Translational Medicine
|
December 16, 2011
Defining the critical hurdles in cancer immunotherapy
Bernard A Fox, Dolores J Schendel, Lisa H Butterfield, et al.
Page
of 5
Search research articles
Search
Showing results (41-50 of 49) with videos related to
Sort By:
Page
of 5
You have reached the last page of results.
This site can display upto 49 results.
Urologia Internationalis
|
February 4, 2024
Sunitinib for Metastatic Renal Cell Carcinoma: Real-World Data from the STAR-TOR Registry and Detailed Literature Review
Annemarie Uhlig, Lothar Bergmann, Martin Bögemann, et al.
BMC Cancer
|
May 1, 2015
Everolimus in metastatic renal cell carcinoma after failure of initial anti-VEGF therapy: final results of a noninterventional study
Lothar Bergmann, Ulrich Kube, Christian Doehn, et al.
Future Oncology (London, England)
|
September 23, 2020
Consensus paper: current state of first- and second-line therapy in advanced clear-cell renal cell carcinoma
Peter J Goebell, Philipp Ivanyi, Jens Bedke, et al.
Onkologie
|
March 15, 2013
Everolimus in metastatic renal cell carcinoma after failure of initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy: results of an interim analysis of a non-interventional study
Lothar Bergmann, Peter J Goebell, Ulrich Kube, et al.
Oncology Research and Treatment
|
April 2, 2014
Treatment algorithm for metastatic renal cell carcinoma--recommendations based on evidence and clinical practice
Lothar Bergmann, Jochaim Beck, Kathrin Bothe, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 31, 2019
Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma
Frede Donskov, Robert J Motzer, Eric Voog, et al.
European Urology
|
September 27, 2023
Nivolumab Switch Maintenance Therapy After Tyrosine Kinase Inhibitor Induction in Metastatic Renal Cell Carcinoma: A Randomized Clinical Trial by the Interdisciplinary Working Group on Renal Tumors of the German Cancer Society (NIVOSWITCH; AIO-NZK-0116ass)
Viktor Grünwald, Philipp Ivanyi, Stefanie Zschäbitz, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 3, 2026
Papillary renal cell carcinoma - exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological review
Marit Ahrens, John Haanen, Laurence Albiges, et al.
Journal of Translational Medicine
|
December 16, 2011
Defining the critical hurdles in cancer immunotherapy
Bernard A Fox, Dolores J Schendel, Lisa H Butterfield, et al.
Page
of 5